全文获取类型
收费全文 | 1817359篇 |
免费 | 137534篇 |
国内免费 | 10282篇 |
专业分类
耳鼻咽喉 | 22892篇 |
儿科学 | 57633篇 |
妇产科学 | 48951篇 |
基础医学 | 254096篇 |
口腔科学 | 51308篇 |
临床医学 | 167327篇 |
内科学 | 352646篇 |
皮肤病学 | 40234篇 |
神经病学 | 137361篇 |
特种医学 | 67835篇 |
外国民族医学 | 282篇 |
外科学 | 269671篇 |
综合类 | 57990篇 |
现状与发展 | 24篇 |
一般理论 | 569篇 |
预防医学 | 133879篇 |
眼科学 | 43600篇 |
药学 | 136626篇 |
121篇 | |
中国医学 | 10924篇 |
肿瘤学 | 111206篇 |
出版年
2021年 | 18163篇 |
2019年 | 17180篇 |
2018年 | 23882篇 |
2017年 | 18901篇 |
2016年 | 19914篇 |
2015年 | 24151篇 |
2014年 | 32893篇 |
2013年 | 44884篇 |
2012年 | 62801篇 |
2011年 | 66238篇 |
2010年 | 40269篇 |
2009年 | 36846篇 |
2008年 | 59326篇 |
2007年 | 62560篇 |
2006年 | 62612篇 |
2005年 | 59291篇 |
2004年 | 55651篇 |
2003年 | 52578篇 |
2002年 | 50032篇 |
2001年 | 94083篇 |
2000年 | 95713篇 |
1999年 | 79027篇 |
1998年 | 20976篇 |
1997年 | 18450篇 |
1996年 | 18336篇 |
1995年 | 17642篇 |
1994年 | 16141篇 |
1993年 | 14557篇 |
1992年 | 57995篇 |
1991年 | 55796篇 |
1990年 | 53449篇 |
1989年 | 51141篇 |
1988年 | 46503篇 |
1987年 | 45237篇 |
1986年 | 42467篇 |
1985年 | 40182篇 |
1984年 | 29469篇 |
1983年 | 25024篇 |
1982年 | 13976篇 |
1979年 | 25613篇 |
1978年 | 17644篇 |
1977年 | 14959篇 |
1976年 | 13918篇 |
1975年 | 14595篇 |
1974年 | 17691篇 |
1973年 | 16995篇 |
1972年 | 15730篇 |
1971年 | 14485篇 |
1970年 | 13459篇 |
1969年 | 12536篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
12.
Depeng Meng Yichen Meng Bingyang Li Guigang Zeng Bin Zhang Chunlin Hou Haodong Lin Yueping Ouyang 《Journal of orthopaedic science》2021,26(3):409-414
BackgroundComminuted patellar fractures are not rare, and the ideal treatment method remains controversial. The present study was conducted to evaluate effects and compare complications of two different methods used to treat comminuted patellar fractures.MethodsFrom March 2010 to August 2016, 102 cases of 34-C2 or 34-C3 comminuted patellar fractures were treated at our hospital, wherein patients received two different treatments: titanium cable tension band with cerclage method (group A) and intrafragmentary screws with X-shaped plating technique (group B). At follow-ups, articular step-off, range of motion (ROM), Lysholm scores, time of union, and complications were recorded and analyzed. Radiographic and clinical data as well as rate of complications were statistically analyzed.ResultsIn total, 87 patients were included in the final analysis (n = 47 in group A and n = 40 in group B). No significant differences were noted in terms of cost of implant, age, gender, rate of 34-C3 fractures, rate of layered inferior pole fractures, postoperative articular step-off and union time. At 2-year follow-up, average Lysholm scores, ROM and rate of complications were (89.0 ± 4.5), (122°±12°) and (27.7%) in group A and (90.2 ± 3.9), (124°±11°) and (17.5%) in group B, respectively, with no significant differences (p > 0.05). The mean time of surgery in group B was shorter than that in group A with significant difference (p < 0.05).ConclusionsTreatment using the intrafragmentary screws and plate method for amenable comminuted patellar fractures achieved similar complication rate and favorable functional outcomes at the 2-year follow-up, which was comparable to the titanium cable tension band with cerclage method. Thus, the intrafragmentary screws and plate method is effective, safe and convenient for 34-C2/C3 comminuted patellar fractures, especially appropriate for patients with layered fragments. 相似文献
13.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
14.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
15.
16.
Clinical & Experimental Metastasis - 相似文献
17.
18.
19.
20.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献